Yousri M Barri

US Patent:

7722858, May 25, 2010

Filed:

Feb 9, 2006

Appl. No.:

11/350660

Inventors:

Sudhir V. Shah - Little Rock AR, US
Alexei G. Basnakian - Little Rock AR, US
Yousri M. Barri - Richardson TX, US

Assignee:

Board of Trustees of the University of Arkansas - Little Rock AR
The United States of America as represented by the Department of Veterans Affairs - Washington DC

International Classification:

A61K 49/00

US Classification:

424 92, 424 934, 435 2, 435 3, 435967, 436 15, 436 16, 436 55, 436 71, 436175, 436177, 436178, 436506, 436811

Abstract:

The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of measuring the level of cLDL and/or autoantibody to cLDL in a sample obtained from this individual. The invention further discloses a method of reducing carbamylation in an individual with a monomeric amino acid or other enzymatic or non-enzymatic inhibitors of carbamylation. The instant invention also provides a method to decrease the level of cLDL by direct elimination of cLDL from the blood or plasma of an individual. The invention also provides a method of treating or preventing atherosclerosis in an individual by inhibiting aggregation and/or deposition of cLDL in the individual.

US Patent:

20030045004, Mar 6, 2003

Filed:

Aug 27, 2002

Appl. No.:

10/228493

Inventors:

Yousri Barri - Richardson TX, US
Sudhir Shah - Little Rock AR, US
Alexei Basnakian - Little Rock AR, US

International Classification:

G01N033/53
G01N033/542
G01N033/92
G01N033/543

US Classification:

436/518000, 436/071000

Abstract:

The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of: measuring the level of carbamylated LDL in a sample obtained from said individual. Further provided is a method of reducing carbamylation in an individual in need of such reducing, comprising the step of:treating said individual with a monomeric amino acid or another enzymatic or non-enzymatic inhibitor of carbamylation. Also provided is a method of preventing carbamylation in an individual with normal renal function, comprising the step of: treating said individual with a monomeric amino acid. Further provided is a method of treating or preventing atherosclerosis in an individual in need of such reducing, comprising the step of: inhibiting aggregation and/or deposition of carbamylated LDL in said individual.